Page 12 - Antoine Papiernik News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Antoine papiernik. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Antoine Papiernik Today - Breaking & Trending Today

European VC Sofinnova Partners raises $540M late-stage crossover healthcare fund


(Pixabay)
Sofinnova Partners has pulled in a healthy €445 million ($540 million) in its latest capital raise as the European venture capital firm seeks out late-stage plays in biotech and medtech.
The fund was “oversubscribed and significantly exceeded its target,” the Paris-based firm said, and with this latest cash boost it s set to continue its focus on European clinical-stage companies “needing scale-up capital” while also supporting “best-in-class companies” in the U.S. and elsewhere.
It did, not however, detail any particular targets it was going after. Other VC firms have said in a COVID-19 world they would focus more on conditions such as infectious diseases and other neglected R&D areas. ....

France General , Antoine Papiernik , Insights For The Life Sciences Industry , Sofinnova Partners , Making Insights , Life Sciences , Venture Capital Vc , பிரான்ஸ் ஜநரல் , அன்டோயின் பப்பிேர்னிக் , நுண்ணறிவு க்கு தி வாழ்க்கை அறிவியல் தொழில் , தயாரித்தல் நுண்ணறிவு , வாழ்க்கை அறிவியல் , நிதி திரட்டல் , துணிகர மூலதனம் வ்ஸீ ,

Noema Pharma Raises CHF54M in Series A Financing


Noema Pharma AG, a Basel, Switzerland-based clinical-stage company targeting orphan neurological disorders, raised a Series A financing round, raising CHF54m ($59m USD).
The round was co-led by Sofinnova Partners and Polaris Partners with participation from new international investors Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates. In conjunction with the funding, Darren Carroll of Polaris Partners and Arthur Franken of Gilde Healthcare joined Antoine Papiernik of Sofinnova Partners on the Board of Directors.
The company intends to use the funds to further develop its clinical-stage pipeline. The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberous sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders. ....

Arthur Franken , Darren Carroll , Noema Pharma , George Garibaldi , Antoine Papiernik , Sofinnova Partners , Polaris Partners , Gilde Healthcare , Luigi Costa , Chief Executive Officer , Chief Medical Officer , Tuberous Sclerosis Complex , Trigeminal Neuralgia , ஆர்தர் வெளிப்படையான , டேரன் கரோல் , ஜார்ஜ் க்யாரிபால்டீ , அன்டோயின் பப்பிேர்னிக் , போழரிச் கூட்டாளர்கள் , லூயிஜி கோஸ்டா , தலைமை நிர்வாகி அதிகாரி , தலைமை மருத்துவ அதிகாரி , கிழங்கு ஸ்க்லரோசிஸ் சிக்கலான , முக்கோண நரம்பியல் ,